Understanding VCAN: Potential Therapies for Cancer (G1462)

Target Name: VCAN

NCBI ID: G1462

VCAN

Understanding VCAN: Potential Therapies for Cancer

VCAN, or Versican core protein (isoform 3), is a protein that is expressed in many different tissues in the body, including the nervous system, endothelial cells, and epithelial cells. It is a member of the canvas gene family, which is characterized by the presence of a specific domain in the extracellular domain of the protein that is responsible for its unique structure and function.

One of the unique features of VCAN is its ability to form a tight cytoskeleton in various cell types. This is accomplished through the presence of a unique heparan sulfate proteoglycan (HSP) domain on the protein, which allows it to interact with other cytoskeleton components and form a stable structure. This structure is important for the proper functioning of the cell, as it helps to maintain cell shape, stability, and integrity.

In addition to its role in cytoskeleton formation, VCAN is also involved in a number of other cellular processes that are important for maintaining tissue homeostasis. For example, it is involved in the regulation of cell adhesion, as well as in the production of various signaling molecules that help to maintain cell survival and proliferation.

VCAN has also been shown to play a role in the development and progression of a number of diseases, including cancer. For example, studies have shown that VCAN is often overexpressed in various types of cancer, and that this overexpression is associated with a number of negative outcomes, including increased cancer cell proliferation and the development of invasive tumors.

Despite these promising findings, much more research is needed to fully understand the role of VCAN in cancer. In particular, there is a need for better understanding of the mechanisms by which VCAN promotes cancer cell growth and progression.

One potential approach to addressing this need is to develop VCAN-based therapies or diagnostic tools that can be used to target the protein in cancer cells. This could involve using techniques such as small molecule inhibitors or antibodies to specifically target the VCAN protein, or using techniques such as live cell imaging or RNA sequencing to study its expression and function in cancer cells.

Another potential approach to studying VCAN in cancer is to use it as a biomarker, or a protein that can be used as an indicator of the presence or absence of cancer cells in a particular tissue or body. This could involve using techniques such as qRT- PCR or Western blot to amplify or detect the VCAN protein in response to the presence of cancer cells, or using techniques such as protein array analysis or mass spectrometry to identify changes in the expression of VCAN in response to cancer treatment.

Overall, VCAN is a complex and fascinating protein that is involved in a number of important cellular processes in the body. While much more research is needed to fully understand its role in cancer, its potential as a drug target or biomarker makes it an important area of study.

Protein Name: Versican

Functions: May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid

The "VCAN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VCAN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets